Los Angeles, CA (PRWEB) January 13, 2014
Like any fighter, Quinton "Rampage" Jackson understands injuries. He himself worked through knee surgery and pain until he found Platelet-Rich Plasma therapy (PRP) in recent years. However, the former UFC champ is disappointed by the recent cancellation of the Bellator 106 pay-per-view event versus Tito Ortiz due to his opponent’s neck fracture. As reported by MMAJunkie.com, Jackson stated, "…throw another opponent at me and still keep the PPV because I trained really hard for this and had my knees fixed." Jackson also extended his sympathy to Ortiz, wishing him a speedy recovery.
On October 28, 2013 Jackson was named to Fox Sports’ "The Top 20 Fights in UFC History" for his classic win against Dan Henderson, a London fight that drew a televised audience of as many as six million viewers in 2007.
James Hays, President and CEO of PlasmaGenix, applauded Jackson’s decision to pursue PRP therapy instead of surgery. Says Hays, "One of the main reasons athletes continue to explore the benefits of platelet-rich plasma therapy (PRP) is that injuries that traditionally took a full season or more to heal and rehab after surgery can now often be resolved in just months or weeks after using this innovative treatment."
The PlasmGenix’s Chief Medical Officer Dr. John Simmonds—an orthopedic surgeon—concurs that a series of non-invasive PRP treatments should be performed before surgery in many cases. "PRP has proven effective for many patients, for many conditions, and for many injuries. Along with other non-surgical approaches, I recommend to a number of patients that they try PRP injections first."
PRP therapy has the potential to supercharge healing. By injecting small, concentrated amounts of a patient’s own blood into damaged tissue, PRP can speed healing and reduce or even eliminate pain. The PlasmGenix uses proprietary methodologies to treat joint and tendon pain, ankle sprains, heel pain, and plantar fasciitis. The Institute also uses PRP injections to improve poor circulation, treat diabetic neuropathy, and HIV neuropathy.
PlasmaGenix is a biologics company located in Inglewood, California. Our three lead products, PlasmaNeu, PlasmaGen and PlasmaPro, have been used for over a decade to treat chronic non-healing wounds and preventing amputations in high risk populations, and peripheral neuropathy associated with HIV and Diabetes. Science has recently shown that the body has enormous potential to heal itself. Regenerative medicine is an exciting area in medicine that is evolving very rapidly and PlasmaGenix is proud to be at the forefront of developing new therapeutics to treat a wide variety of chronic conditions. We can now deliver products to accelerate the body’s own natural healing mechanisms and enrich the body’s inherent ability to repair and regenerate.
The culmination of over 3 decades of clinical experience and research gave birth to PlasmaGenix which is poised to be a leader in the field of regenerative medicine. To date, PlasmaGenix has successfully treated over 10,000 patients for various neurologic conditions, chronic non-healing wounds, sports related injures as well as muscular sclerosis and Charcot-Marie Tooth disease.